|
Page: 1. Letter from the Executive Director 1. Update International IP Research Consortium 2. NIPF Holds Second Fundraiser
Each year since its creation, the National Incontinentia Pigmenti Foundation has experienced growth. Our membership has grown to over 700, and our annual contributions have almost doubled. Unfortunately our financial needs have also increased. The International IP Research Consortium, which began with 3 participating laboratories in 3 countries, now consists of 6 laboratories in 6 countries. The 4th biannual meeting is scheduled for June 6-7, 1998. The number of inquiries via the website on the internet has increased dramatically from 2-3 per week to several each day. In the Spring 1997 newsletter I introduced the first in a series of articles dealing with the complex issues faced by those with a genetic disorder or who are the parents or siblings. I began with the feelings that occur when a mother gives birth to a child with a genetic disorder. In this issue I have tried to concentrate on the emotions of the siblings. The sibling with the disorder, the sibling without and the parents reactions to them. We are embarking on two new projects. First, an active fundraising campaign. With the assistance of two experts in the field of financial solicitation, both of whom are members of NIPF and who are volunteering their services, we will begin to submit grant applications to private and public foundations. This is a difficult task for a rare disorder that most recipients of the application will not be familiar with. The other new project, which we will shortly be working on, is a clinical questionnaire to help analyze and study the symptoms of IP. The questionnaire is almost fully developed and ready for mailing, and the computer program that will be analyzing the responses is being designed. A more detailed description of this project is below. I am proud to state that the third year of operation has ended on a very high and hopeful note. Susanne Bross Emmerich |
By far the most exciting project being undertaken by the Foundation is the International IP Research Consortium. In the winter of 1996, the consortium consisted of three laboratories: University of Cambridge, Cambridge, England; Hopital des Enfants-Malades, Paris, France and Baylor College of Medicine, Houston Texas. Since then the number of participating institutions has grown to six and now includes the International Institute of Genetics and Biophysics, Naples, Italy; University Hospital, Uppsala, Sweden, and German Cancer Research Center, Heidelberg, Germany. Every six months the consortium meets at one of the participating labs. To date the meetings have been held in France, England, Italy, and this June 1998 Germany. As we are keen to economize, the meetings are always held over a weekend as the flights are significantly less expensive at that time. All those attending arrive either Friday night or Saturday morning. Everyone stays in the same hotel, the arrangements having been made by the host institution. Usually each laboratory sends two of the people who are working on the project, but the host laboratory usually has the whole team present, which in some cases consists of as many as 6 researchers. Typically the first meeting begins early Saturday afternoon. After greetings the business of the meeting gets underway. A prepared agenda is distributed which consists of the order in which each researcher presents their latest work. Slides, charts, overheads, graphs, etc. are shown with each presentation. The meeting, which is very intense, often lasts until 6 P.M. with only a brief coffee break. The group then returns to its lodgings and reassembles for dinner. This is a very festive occasion, as the group, which has only been communicating via e-mail and has not met for six months, has grown genuinely fond of one another. Weather permitting, a little sight seeing is sometimes included after the meal. Early the next morning, members meet for breakfast, and then it is immediately off to the lab to continue the session. All prepared presentations are finished, and now there is an open discussion. A brief break for lunch, and then back to the data. At the conclusion, - the next meeting is scheduled, and each member discusses what aspect of the research he or she will concentrate on for the next 6 months. The consortium is also a wonderful experience in international relations. Although 6 countries are represented there are about 8 different nationalities. English, which is the common language, is spoken both in the meetings and at meal times, with occasional side conversations in French. One of the most important members of this group, who has been working on IP long before the start of the consortium, is Asmae Smahi, Ph.D. Dr. Smahi has been working in Paris for about 7 years, and is vital to the success of this project. Dr. Smahi is an Algerian citizen who, due to current French law, cannot be employed in France. To date, the lab has been funding her with grants they have received from private donations and foundations. This funding is no longer available. The NIPF considers her so critical to this project, that it has agreed to pay her full salary. It is, and will always be, impossible to fund a laboratory, as genetic research is one of the most expensive undertakings in this day and age. The costs run into the many millions of dollars. However, the next best option is to be able to fund the person who conducts the actual research. As you are all aware, research to identify the IP gene is one of the major goals of NIPF. We are extremely pleased that we have raised enough funding to be able to support Dr. Smahi. However, the continued support of our membership is vital if we are to continue this work. In conclusion, I wish I could give an exact date when the gene will be found Unfortunately this is not possible, but the consortium is continually getting closer and its members have no doubt that it will happen. |
The International IP Research Consortium will one day, in the not too distant future, isolate the IP gene In the process of understanding IP, this is obviously a very crucial step. But, as difficult as that is, it is only the first step. The second phase of understanding IP is to study the gene after it has been identified, to understand exactly what it is or is not doing that causes the various symptoms to occur. For the scientists to accomplish this they must have specific clinical information available to them. That information consists of knowing details of the specific symptoms, and their frequency, that are caused by IP. As we know, IP is a very multi-symptomatic disorder, and therefore affects many different organ systems. Not only do the symptoms vary widely, but so does severity. Although many articles have been written about IP for medical journals, to my knowledge no statistical analysis on this scale has been made. Frequently families and physicians want data of the various symptoms. At this moment those answers are largely guesswork. Several hundred copies of the questionnaire about which I am writing will be mailed out locally and internationally. Copies will be sent to physicians all over the world who are known to have IP patients. It will also go to the members of the IP consortium and it will go to all those in the NIPF database. This includes patients, families, physicians, genetic counselors, anyone who is in contact with someone who has IP The questionnaire can be filled out either by the physicians who are caring for someone with IP, or the parent of a child with IP, or a person with IP. This is a somewhat arduous task because it will require the cooperation of a variety of medical providers, or become the time consuming task of either a parent or an affected individual. Some questions can perhaps not be answered in each case for any number of reasons, but hopefully everyone will do their best. To make this project successful it is necessary to have the cooperation of those to whom the questionnaire will be sent. It is not a project that will provide definitive answers immediately. It is a long-term project. It will take time for the mailing, responses, and the statistical analysis to be done. But it is a beginning, and it is a project about which all those who are in the field of genetics and all those who are specifically interested in IP are very enthusiastic. One of the overriding concerns of everyone is of course confidentiality. The responses will carry a code, and the option will exist for total anonymity. IF so desired, no one need know the identity of the individual about whom the form is filled out. If an individual does not feel strongly about anonymity, it is helpful to know the identity of the individual. But it is a choice one has. The need for a code is to ensure that no one is in the survey more than once (which would skew the statistics). Therefore the code has been designed to detect duplication. This project will be administered by and conducted under the auspices of The Baylor College of Medicine in Houston Texas. Dr. David Nelson, head of the laboratory at Baylor which is American member of the International IP Research Consortium, and Dr. Richard Lewis, also at Baylor, and a member of the NIPF Scientific Advisory Council, are in charge of the study. Now in the process of being developed is a computer program to do the analysis and statistical work. Drs. Nelson and Lewis, all the members of the IP Consortium and NIPF, appreciate your cooperation and that of your caregivers in helping with this important effort.
|
Spring 1998 Page 2
Spring 1998 page 3